The Conversation (0)
The Street reports, via Kapitall Wire, on how the US Drug Quality and Security Act, making its way through the US Congress, will prohibit pharmacies from copying widely available, FDA-approved drugs in their compounded medications.
The Street reports, via Kapitall Wire, on how the US Drug Quality and Security Act, making its way through the US Congress, will prohibit pharmacies from copying widely available, FDA-approved drugs in their compounded medications.
As quoted in the market news:
If Congress passes the Drug Quality and Security Act, pharmaceutical companies may see increased sales due to this restriction, which would bar compounding pharmacies from copying their drugs. This inspired us to look for investment opportunities among pharmaceutical stocks for our following screen.